IACH News Podcasts

Give the high rate of advances in the field of clinical hematology, the IACH News initiative enables experts in the field and key opinion leaders share the most up to date information in a timely manner, and in a format that is, focused, engaging and easy to access.

December 7th- ASH 2025 Spotlight: The Rise of Golcadomide

CME Congresses .

December 7th- ASH 2025 Spotlight: The Rise of Golcadomide

December 7th- ASH25 Highlights: What’s New in Lymphoid Malignancies at #ASH25?

CME Congresses .

December 7th- ASH25 Highlights: What’s New in Lymphoid Malignancies at #ASH25?

December 6th- ASH 2025 Spotlight: The VERIFY Trial

CME Congresses .

December 6th- ASH 2025 Spotlight: The VERIFY Trial

December 6th- ASH 2025 Spotlight: The HD21 Trial

CME Congresses .

December 6th- ASH 2025 Spotlight: The HD21 Trial

December 3rd- Sequencing BCMA‐ and GPRC5D‐targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network - PMC

CME Congresses .

December 3rd- Sequencing BCMA‐ and GPRC5D‐targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network – PMC

December 1st- Prof. Florent Malard- What to expect at #ASH25 in GVHD

CME Congresses .

December 1st- Prof. Florent Malard- What to expect at #ASH25 in GVHD

November 28th- ASH 2025 Late-Breaking Preview- LBA-1: inMMyCAR Phase 1, KLN-1010 in RRMM

CME Congresses .

November 28th- ASH 2025 Late-Breaking Preview- LBA-1: inMMyCAR Phase 1, KLN-1010 in RRMM

November 27th- Optimizing the Use of Melflufen in Relapsed/Refractory Multiple Myeloma

CME Congresses .

November 27th- Optimizing the Use of Melflufen in Relapsed/Refractory Multiple Myeloma

November 25th- Prof. Mohamad Mohty- Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3

CME Congresses .

November 25th- Prof. Mohamad Mohty- Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3

November 25th- Prof. Mohamad Mohty- What to Expect at #ASH25 in Multiple Myeloma

CME Congresses .

November 25th- Prof. Mohamad Mohty- What to Expect at #ASH25 in Multiple Myeloma